Form 4: Contineum Therapeutics Director Miralles Gines Diego Reports Stock Option Grant

Director Miralles Gines Diego reports the acquisition of stock options in Contineum Therapeutics, Inc.

Summary

• On March 14, 2025, Director Miralles Gines Diego acquired stock options to purchase 29,500 shares of Contineum Therapeutics, Inc. (CTNM) Class A Common Stock at an exercise price of $6.67.
• The options were granted under the Issuer's 2024 Equity Incentive Plan, pursuant to the Issuer's Non-Employee Director Compensation Program, as amended.
• One-third of the option shares vest on March 14, 2026, and the remainder vests in 24 equal monthly installments thereafter, subject to continuous service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock options is a standard practice and indicates confidence in the company's future.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing him to work towards the company's success.

Industry Context

Stock option grants to directors are a common practice in the biotechnology industry to incentivize and retain talent.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one-third after one year and the remainder over 24 months is a typical vesting arrangement.
• Comparing the size of the grant (29,500 shares) to similar companies would require analyzing director compensation packages at peer companies of Contineum Therapeutics.

Stakeholder Impact

• The stock option grant could have a slightly dilutive effect on existing shareholders if the options are exercised in the future.

Key Dates